マイトジェン活性化プロテインキナーゼ3治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Mitogen Activated Protein Kinase 3 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0386
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Mitogen Activated Protein Kinase 3 – Pipeline Review, H2 2019
Summary

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Mitogen-activated protein kinase 3 is an enzyme encoded by the MAPK3 gene. It acts in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. It is activated by upstream kinases resulting in its translocation to the nucleus where it phosphorylates nuclear targets.

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) pipeline Target constitutes close to 11 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Musculoskeletal Disorders which include indications Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Knee Osteoarthritis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report Mitogen Activated Protein Kinase 3 – Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Overview
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Companies Involved in Therapeutics Development
Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Eli Lilly and Co
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Shanghai Green Valley Pharmaceutical Co Ltd
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Drug Profiles
ASN-007 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTX-029 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATG-017 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JSI-287 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KO-947 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3214996 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8353 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sprifermin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Dormant Products
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Discontinued Products
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) – Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Asana BioSciences to present phase 1 clinical safety and efficacy data of oral, once-weekly, ASN007, a novel ERK 1/2 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 08, 2019: EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
May 15, 2019: Eli Lilly presents update on ERK inhibitor, LY3214996 at ASCO 2019
Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress
Apr 10, 2018: Asana BioSciences Announces Presentations of ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
Apr 09, 2018: Kura Oncology Presents Poster on KO-947 at AACR Annual Meeting 2018
Feb 22, 2018: Phase I Clinical Trial Shows Promise as Investigational Drug for Melanoma
Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries’ BVD523
May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antengene Corp, H2 2019
Pipeline by Asana BioSciences LLC, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioMed Valley Discoveries Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Kalyra Pharmaceuticals Inc, H2 2019
Pipeline by Kura Oncology Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Shanghai Green Valley Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Eli Lilly and Co
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Shanghai Green Valley Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[マイトジェン活性化プロテインキナーゼ3治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆